Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2025)

Ultragenyx Pharmaceutical has reported Intangibles over the past 9 years, most recently at $176.0 million for Q4 2025.

  • Quarterly Intangibles fell 1.12% to $176.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $176.0 million through Dec 2025, down 1.12% year-over-year, with the annual reading at $176.0 million for FY2025, 1.12% down from the prior year.
  • Intangibles was $176.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $172.9 million in the prior quarter.
  • Over five years, Intangibles peaked at $178.0 million in Q4 2024 and troughed at $130.9 million in Q3 2021.
  • The 5-year median for Intangibles is $161.9 million (2022), against an average of $159.4 million.
  • Year-over-year, Intangibles rose 24.76% in 2022 and then decreased 1.12% in 2025.
  • A 5-year view of Intangibles shows it stood at $131.3 million in 2021, then increased by 24.76% to $163.8 million in 2022, then rose by 6.11% to $173.8 million in 2023, then rose by 2.43% to $178.0 million in 2024, then dropped by 1.12% to $176.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Intangibles are $176.0 million (Q4 2025), $172.9 million (Q3 2025), and $174.7 million (Q2 2025).